Airain ltd Invests $3.52 Million in Catalent Inc (CTLT)
Airain ltd bought a new position in shares of Catalent Inc (NASDAQ:CTLT) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 100,401 shares of the company’s stock, valued at approximately $3,524,000. Airain ltd owned about 0.08% of Catalent as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in CTLT. Chicago Equity Partners LLC boosted its stake in shares of Catalent by 22.4% in the first quarter. Chicago Equity Partners LLC now owns 91,225 shares of the company’s stock worth $2,583,000 after buying an additional 16,720 shares during the period. State Treasurer State of Michigan boosted its position in shares of Catalent by 1.0% in the first quarter. State Treasurer State of Michigan now owns 50,700 shares of the company’s stock worth $1,436,000 after buying an additional 500 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in shares of Catalent by 4.2% in the first quarter. Great West Life Assurance Co. Can now owns 72,999 shares of the company’s stock worth $2,065,000 after buying an additional 2,966 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of Catalent by 1.4% in the first quarter. Oregon Public Employees Retirement Fund now owns 42,605 shares of the company’s stock worth $1,207,000 after buying an additional 600 shares during the last quarter. Finally, Emerald Advisers Inc. PA boosted its position in shares of Catalent by 34.1% in the first quarter. Emerald Advisers Inc. PA now owns 99,013 shares of the company’s stock worth $2,804,000 after buying an additional 25,177 shares during the last quarter.
Catalent Inc (NASDAQ:CTLT) opened at 35.36 on Tuesday. The company has a market cap of $4.42 billion and a PE ratio of 41.65. The firm’s 50-day moving average is $35.14 and its 200 day moving average is $32.37. Catalent Inc has a 1-year low of $21.83 and a 1-year high of $38.73.
Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.08. The firm had revenue of $616.90 million for the quarter, compared to the consensus estimate of $547.48 million. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.52 EPS. Analysts predict that Catalent Inc will post $1.59 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on the stock. J P Morgan Chase & Co upped their price target on shares of Catalent to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday. Piper Jaffray Companies reiterated an “overweight” rating and issued a $45.00 price target on shares of Catalent in a research note on Tuesday. William Blair upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a research note on Monday, May 15th. Bank of America Corporation reiterated a “buy” rating and issued a $37.00 price target (up previously from $32.00) on shares of Catalent in a research note on Wednesday, May 17th. Finally, Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Catalent currently has an average rating of “Buy” and a consensus target price of $34.88.
In related news, SVP Christine Dolan sold 745 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $34.85, for a total transaction of $25,963.25. The transaction was disclosed in a filing with the SEC, which is available at this link.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.